Author : A. J. Thanoon, Imad
The Medical Journal of Basrah University,
Volume 25, Issue 2, Pages 23-27
Objective: To assess, oxidative stress (by measuring malondialdehyde "MDA" which reflects lipid peroxidation, and
total antioxidant status "TAS"), and immunoglobulin levels (IgA, IgG, IgM) in patients with Hodgkin's lymphoma
before and one month after starting cytotoxic drugs, in comparison with controls.
Design: Case-control study
Setting: This study was conducted in the Hospital of Nuclear Medicine and Department of Pharmacology, College of
Medicine, University of Mosul.
Patients and Methods: Twenty-three patients with Hodgkin’s lymphoma were included in this study together with 24
apparently healthy subjects taken as a control. Initially for both patients and control, serum MDA, TAS and
immunoglobulin levels (IgA, IgG, IgM) were measured and reported one month from starting specific cytotoxic drugs
for the patient groups and after one month gap period for the control using especial commercial kits from Randox
company (UK), for measuring TAS and immunoglobulin levels, while measurement of MDA was done by laboratory
Results: Before starting cytotoxic regimen, there was a highly significant rise in serum MDA concentration in
patients with Hodgkin's lymphoma in comparison with control. After one month from starting cytotoxic regimen,
there was a highly significant rise in serum MDA concentration and a significant reduction in TAS and serum
immunoglobulin levels. By comparing the period before and after starting cytotoxic regimen in patients with
lymphoma, there was a significant rise in MDA and a significant reduction in TAS and immunoglobulin levels with
the exception of IgM which showed insignificant reduction.
Conclusion: This study revealed a rise in the oxidative stress; to which patients with Hodgkin's lymphoma were liable
to, by the effect of specific cytotoxic regimen. This is reflected by the rise in the serum level of MDA and a reduction
in the TAS after cytotoxic regimen. It also indicated a reduction in immunity of such patients during cytotoxic
regimen as reflected by a reduction in immunoglobulin levels.